SUMO1
Reaktivität: Human
WB, ELISA, IHC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
ELISA: 1/1,000. Western blot: 1/100-1/500. Immunohistochemistry on paraffin sections: 1/50-1/100. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.25 mg/mL
Buffer
PBS containing 0.09 % (W/V) Sodium Azide as preservative
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Target
SUMO1
(Small Ubiquitin Related Modifier Protein 1 (SUMO1))
Covalent modification of target lysines by SUMO (small ubiquitin-like modifier) modulates processes such as protein localization, transcription, nuclear transport, mitosis, DNA replication and repair, signal transduction, and viral reproduction. SUMO does not seem to be involved in protein degradation and may in fact function as an antagonist of ubiquitin in the degradation process. The SUMO family consists of SUMO1 and closely related homologs SUMO2, SUMO3, and SUMO4. Sumoylation has been shown to regulate a wide range of proteins, including MDM2, PIAS, PML, RanGAP1, RanBP2, p53, p73, HIPK2, TEL, c-Jun, Fas, Daxx, TNFRI, Topo-I, Topo-II, PARK2, WRN, Sp100, IkB-alpha, Androgen receptor (AR), GLUT1/4, CaMK, DNMT3B, TDG, HIF1A, CHD3, EXOSC9, RAD51, and viral targets such as CMV-IE1/2, EBV-BZLF1, and HPV/BPV-E1.Synonyms: GMP1, HSMT3, PIC1, SMT3 homolog 1, SMT3B, SMT3C, SMT3H1, SMT3H2, SMT3H3, SUMO-1, SUMO-2, SUMO-3, Sentrin, Sentrin-2, Small ubiquitin-like modifier, UBL1